Charles L Shapiro, MD Email Charles Shapiro

2013
Physicians recognized for being in the top 10 percent for patient satisfaction, nationally

2005
America's Top Doctors for Cancer

2005
Bertha Bouroncle Teaching Award

2001
America's Top Doctors

1998
Best Doctors in America

1991
American Cancer Society Clinical Oncology Career Development
American Cancer Society

The James Champion Award
James Cancer Hospital

Bacilli Award for Academic Excellence
University of Buffalo Medical School

John Watson Award for Scholarship in Medicine
University of Buffalo Medical School

Alpha Omega Alpha

New topic
The focus of my research is investigator-initiated early phase clinical trials in breast cancer.  Areas of interest include: breast cancer survivorship, in particular the impact and treatment of adjuvant chemotherapy-induced bone loss in premenopausal women; microRNA profiling of triple negative breast cancers to define subsets that have better or worse prognosis; and preclinical evaluations of novel drugs in collaboration with a medicinal chemist, including a PDK-1 inhibitor, AMP kinase inhibitor and the PARP inhibitors.  At Mount Sinai I plan to form collaborations with laboratory-based scientists to evaluate novel drugs preclinically, develop investigator-initiated trials to further define subsets of triple negative breast cancers using genomic methods, and to conduct investigator-initiated trials in breast cancer survivorship.

Oh WK, Manola J, George DJ, Fierman A, Fontaine-Rothe P, Morrissey S, Prisby J, Kaufman DS, Shapiro CL, Kantoff PW, Smith MR. A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. Cancer investigation 2002; 20(2).

Woodard S, Nadella PC, Kotur L, Wilson J, Burak WE, Shapiro CL. Older women with breast carcinoma are less likely to receive adjuvant chemotherapy: evidence of possible age bias?. Cancer 2003 Sep; 98(6).

Carson WE, Shapiro CL, Crespin TR, Thornton LM, Andersen BL. Cellular immunity in breast cancer patients completing taxane treatment. Clinical cancer research : an official journal of the American Association for Cancer Research 2004 May; 10(10).

Speeg KV, Maldonado AL, Liaci J, Muirhead D. Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo. Hepatology (Baltimore, Md.) 1992 May; 15(5).

Mrozek E, Shapiro CL. Survivorship and complications of treatment in breast cancer. Clinical advances in hematology & oncology : H&O 2005 Mar; 3(3).

Ramaswamy B, Povoski SP, Rhoades C, Allen J, Hauger M, Young D, Burak W, Farrar W, Yee L, Kendra K, Somasundaram S, Orlowski RZ, Shapiro CL. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer. Breast cancer research and treatment 2005 Sep; 93(1).

Mrozek E, Ramaswamy B, Young D, Rhoades CA, Kendra K, Allen J, Moore T, Hauger M, Watson H, Merriman N, Nadella P, Villalona-Calero M, Shapiro CL. Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Clinical breast cancer 2006 Jun; 7(2).

Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Sep; 25(25).

Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH. Breast cancer risk reduction. Journal of the National Comprehensive Cancer Network : JNCCN 2010 Oct; 8(10).

Yang HC, Thornton LM, Shapiro CL, Andersen BL. Surviving recurrence: psychological and quality-of-life recovery. Cancer 2008 Mar; 112(5).

Pant S, Landon MB, Blumenfeld M, Farrar W, Shapiro CL. Treatment of breast cancer with trastuzumab during pregnancy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Mar; 26(9).

Guler G, Huebner K, Himmetoglu C, Jimenez RE, Costinean S, Volinia S, Pilarski RT, Hayran M, Shapiro CL. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer 2009 Feb; 115(4).

Liu JJ, Shen R, Chen L, Ye Y, He G, Hua K, Jarjoura D, Nakano T, Ramesh GK, Shapiro CL, Barsky SH, Gao JX. Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. International journal of clinical and experimental pathology 2010; 3(4).

Lee KH, Hsu EC, Guh JH, Yang HC, Wang D, Kulp SK, Shapiro CL, Chen CS. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. The Journal of biological chemistry 2011 Nov; 286(45).

Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CL. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer chemotherapy and pharmacology 2012 Jul; 70(1).

Gasparini P, Fassan M, Cascione L, Guler G, Balci S, Irkkan C, Paisie C, Lovat F, Morrison C, Zhang J, Scarpa A, Croce CM, Shapiro CL, Huebner K. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. PloS one 2014; 9(2).